Rifaximin in Patients With Monoclonal Gammopathy

NCT03820817 ↗

Phase 1 Completed 50 enrolled Emory University National Cancer Institute (NCI) · collab

NaSingle-groupOpen-labelTreatment

Summary

This trial studies how well rifaximin works in treating patients with monoclonal gammopathy. Antibiotics, such as rifaximin, may help to kill bacteria in the intestines and reduce the abnormal protein or cells in patients with monoclonal gammopathy.

Timeline

Start: 2019-05-15
Primary completion: 2025-11-30
Completion: 2025-11-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Rifaximin	Other / unclassified	—	Oral

Rifaximin in Patients With Monoclonal Gammopathy

Summary

Timeline

Drugs

Indications